<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00813293</url>
  </required_header>
  <id_info>
    <org_study_id>08-256</org_study_id>
    <secondary_id>K23CA139005</secondary_id>
    <secondary_id>IST000508</secondary_id>
    <nct_id>NCT00813293</nct_id>
  </id_info>
  <brief_title>Sorafenib Therapy Prior to Radiofrequency Ablation for Intermediate Sized Hepatocellular Cancer</brief_title>
  <official_title>Randomized, Double-Blind, Placebo-Controlled, Phase II Trial Of Short Course Sorafenib Therapy Prior to Radiofrequency Ablation for Intermediate Sized (3.5 to 7cm) Hepatocellular Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Beth Israel Deaconess Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Dana-Farber Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Brigham and Women's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Onyx Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Dana-Farber Cancer Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this research study is to determine if sorafenib improves the effectiveness of
      a procedure called radiofrequency ablation for the treatment of hepatocellular cancer. During
      radiofrequency ablation (RF ablation) a needle is inserted into the tumor tissue and heat is
      used to kill the tumor cells.

      Sorafenib has been approved by the FDA for the treatment of hepatocellular cancer that cannot
      be treated with surgery. Radiofrequency ablation has been used to treat many types of tumors,
      including hepatocellular cancers. Pre-clinical data suggests that sorafenib may improve the
      efficacy of RFA. The use of sorafenib prior to RF ablation in this study is &quot;investigational&quot;
      and has not been approved by the FDA. &quot;Investigational&quot; means that this combination is still
      being studied and that research doctors are trying to find out more about it. In this study,
      the study doctors hope to better understand the extent to which the combination of sorafenib
      and RFA may be done practically and successfully. Correlative imaging and tumor studies will
      evaluate mechanisms of action as well as novel predictors of RFA efficacy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Participants will be randomized to receive either sorafenib or placebo (pills with no
      medication). Participants will take sorafenib or placebo on Days 1-9. Radiofrequency ablation
      will be performed by an interventional radiologists on Day 10.

      On Days 1 and 9 of the study participants will have a physical exam and blood tests
      performed. A study MRI will be performed at Beth Israel Deaconess Medical Center (BIDMC)
      prior to starting study medication and on Day 9. A tumor biopsy will be obtained at the time
      of RFA. A CT scan will be performed after RFA.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">January 2009</start_date>
  <completion_date type="Anticipated">December 2017</completion_date>
  <primary_completion_date type="Actual">December 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To prospectively investigate if sorafenib increases the effectiveness of RFA.</measure>
    <time_frame>2 years</time_frame>
    <description>Difference in volume and diameter of coagulation zone</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>To describe the safety and feasibility of sorafenib prior to RFA.</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To explore the relationship between MRI and RFA effectiveness</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To investigate tumor tissue for changes after sorafenib and to assess for RFA predictors</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Hepatocellular Cancer</condition>
  <arm_group>
    <arm_group_label>Intervention Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sorafenib treatment given prior to radiofrequency ablation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Arm</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo pills given prior to radiofrequency ablation</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sorafenib</intervention_name>
    <description>Short course of sorafenib given orally twice a day prior to RFA</description>
    <arm_group_label>Intervention Arm</arm_group_label>
    <other_name>Nexavar</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>radiofrequency ablation</intervention_name>
    <description>all patients receive standard of care radiofrequency ablation</description>
    <arm_group_label>Intervention Arm</arm_group_label>
    <arm_group_label>Placebo Arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Confirmed hepatocellular cancer (HCC) by pathology or by NCCN imaging guidelines

          -  All HCC stages are allowed. May be a liver transplant candidate.

          -  At least one tumor (index tumor) accurately measured as 3.5-7cm in diameter (long and
             short axis diameter to be recorded, but only one needs to meet this criteria) on
             baseline imaging.

          -  No prior therapy for the index tumor

          -  No prior systemic treatment for HCC within 4 weeks and no prior anti-VEGF therapy
             within 8 weeks of study entry.

          -  Life expectancy &gt; 8 weeks.

          -  ECOG &gt;=0 or 1

          -  RFA clinically indicated for index tumor.

          -  Acceptable overall RFA and anesthesia risk.

          -  Adequate bone marrow, liver and renal function: Hemoglobin &gt;9.0 g/dl; Absolute
             neutrophil count (ANC)&gt;1,500/mm3; Platelet count correctable to &gt;50,000/mm3;
             compensated liver function (Child-Turcotte-Pugh A, B7 or B8); Creatinine &lt;1.5 times
             ULN; INR correctable to &lt;1.5.

          -  Ability to take oral medication and no evidence of impaired absorption.

        Exclusion Criteria

          -  Urgent treatment of the index tumor anticipated.

          -  Participants who have not recovered from adverse events due to agents administered
             more than 4 weeks earlier. Participants currently receiving any other study agents.

          -  Known brain metastases

          -  History of allergic reactions attributed to compounds of similar chemical or biologic
             composition to sorafenib.

          -  Participants receiving medications or substances that are inducers of CYP3A4
             (rifampicin, St. John's wort, phenytoin, carbamazepine, phenobarbital and
             dexamethasone) or that are metabolized/eliminated by predominantly UGT1A1 pathway or
             by CYP2B6 and CYP2C8.

          -  Decompensated liver disease

          -  Uncontrolled hypertension

          -  Thrombolic or embolic events within the past 6 months.

          -  Hemorrhage/bleeding event within 4 weeks

          -  Serious non-healing wound, ulcer, or bone fracture.

          -  Evidence of severe or uncorrectable bleeding diathesis or coagulopathy

          -  Major surgery, open biopsy or significant traumatic injury within 4 weeks of study
             entry.

          -  Contraindication to or inability to undergo the RFA procedure,

          -  Contraindication to or inability to undergo imaging with MRI

          -  Uncontrolled intercurrent illness

          -  Individuals with a history of a different malignancy unless disease-free for at least
             5 years and are deemed by the Investigator to be at low risk for recurrence.
             Individuals with the following cancers are eligible if diagnosed and treated within
             the past 5 years: cervical cancer in situ, and basal cell or squamous cell carcinoma
             of the skin.

          -  HIV-positive individuals on combination antiretroviral therapy

        For additional inclusion/exclusion criteria details contact Study Site.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rebecca A Miksad, MD, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>Beth Israel Deaconess Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Dana-Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beth Israel Deaconess Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Hakim√© A, Hines-Peralta A, Peddi H, Atkins MB, Sukhatme VP, Signoretti S, Regan M, Goldberg SN. Combination of radiofrequency ablation with antiangiogenic therapy for tumor ablation efficacy: study in mice. Radiology. 2007 Aug;244(2):464-70.</citation>
    <PMID>17641366</PMID>
  </reference>
  <verification_date>February 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 22, 2008</study_first_submitted>
  <study_first_submitted_qc>December 22, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 23, 2008</study_first_posted>
  <last_update_submitted>February 23, 2017</last_update_submitted>
  <last_update_submitted_qc>February 23, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">February 27, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Dana-Farber Cancer Institute</investigator_affiliation>
    <investigator_full_name>Rebecca Miksad, MD, MPH</investigator_full_name>
    <investigator_title>Assistant Professor, Harvard University; Attending Physician, Beth Israel Deaconess Medical Center</investigator_title>
  </responsible_party>
  <keyword>Hepatocellular Cancer</keyword>
  <keyword>HCC</keyword>
  <keyword>Liver Cancer</keyword>
  <keyword>radiofrequency ablation</keyword>
  <keyword>RFA</keyword>
  <keyword>sorafenib</keyword>
  <keyword>nexavaar</keyword>
  <keyword>liver directed therapy</keyword>
  <keyword>interventional radiology</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sorafenib</mesh_term>
    <mesh_term>Niacinamide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

